As part of its recent investigation into direct-to-consumer genetic tests, the US Food and Drug Administration last week sent letters to DTC firms 23andMe, Decode Genetics, Knome, and Navigenics, as well as to Illumina, requesting information on why they believe their tests or platforms do not need to be cleared by the agency.